BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.99
+0.04 (0.45%)
At close: Jun 18, 2026, 4:00 PM EDT
9.02
+0.03 (0.33%)
After-hours: Jun 18, 2026, 7:48 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, BioCryst Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.3. The average 1-year stock price forecast is 136.93% higher than the current stock price, while the lowest is $13 (+44.61%) and the highest is $32 (+255.95%).
Price Target: $21.3 (+136.93%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 7, 2026.
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +133.59% | May 7, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +211.46% | May 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $32 | Buy | Maintains | $32 | +255.95% | May 7, 2026 |
| Needham | Needham | Buy Maintains $18 → $16 | Buy | Maintains | $18 → $16 | +77.98% | May 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $30 | Buy | Maintains | $30 | +233.70% | May 6, 2026 |
Financial Forecast
Revenue This Year
671.03M
from 874.84M
Decreased by -23.30%
Revenue Next Year
727.22M
from 671.03M
Increased by 8.37%
EPS This Year
0.57
from 0.63
Decreased by -10.98%
EPS Next Year
0.68
from 0.57
Increased by 20.35%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 732.5M | ||
| Avg | 671.0M | ||
| Low | 645.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -16.3% | ||
| Avg | -23.3% | ||
| Low | -26.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.73 | ||
| Avg | 0.57 | ||
| Low | 0.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 15.0% | ||
| Avg | -11.0% | ||
| Low | -37.0% |